Larvol Delta - FRONTIER-A-Feasibility-Study-to-Evaluate-the-Safety-of-the-TheraSphere-Glioblastoma-GBM-Device-in-Patients-With-Recurrent-GBM

TheraSphere (yttrium 90 microspheres) - Boston Scientific

http://clinicaltrials.gov/ct2/show/NCT05303467

Jun 24, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next